Epirubicin clinical trials
Also written Ellence and Farmorubicin.
Related medicines add 2 studies
Counted the way a researcher would: Epirubicin with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Epirubicin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Epirubicin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Sept 1999 · ELLENCE · NDA 050778 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
153 studies that test it; most in 2002 (12)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1993 | 1 |
| 1996 | 5 |
| 1997 | 2 |
| 1998 | 3 |
| 1999 | 2 |
| 2000 | 8 |
| 2001 | 11 |
| 2002 | 12 |
| 2003 | 11 |
| 2004 | 7 |
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 9 |
| 2008 | 11 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 3 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 149
Fudan University (7) · Hellenic Oncology Research Group (5) · Cancer Trials Ireland (4) · Royal Marsden NHS Foundation Trust (4) · Hebei Medical University Fourth Hospital (3) · NCIC Clinical Trials Group (3) · NSABP Foundation Inc (3) · SCRI Development Innovations, LLC (3)
Often tested with
Tested in the same studies.
Cyclophosphamide (55) · Docetaxel (48) · Paclitaxel (36) · Fluorouracil (23) · Capecitabine (21) · Cisplatin (19) · Carboplatin (18) · Gemcitabine (9)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 11 phase 3 studies under way
Epirubicin is the comparator. A study of two new drugs counts under both.
- 4Carboplatin · Fudan University · next primary completion Jun 2029
- 2Paclitaxel · Fudan University
- 1Datopotamab deruxtecan · AstraZeneca · next primary completion Nov 2028
- 1Cisplatin · Dutch Colorectal Cancer Group
- 1Capecitabine · Dutch Colorectal Cancer Group
- 1Docetaxel · Fudan University · next primary completion Aug 2028
- 1Cyclophosphamide · Fudan University · next primary completion Aug 2028
- 1Sacituzumab tirumotecan · Merck Sharp & Dohme LLC · next primary completion Mar 2033
Reaching primary completion within a year · 7, 1 in phase 3
Studies that test Epirubicin, phase 3 first.
- Dec 2026Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast CancerPhase 2/3 · Hebei Medical University Fourth Hospital
- Dec 2026A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of BreastPhase 1 · Shanghai Jiao Tong University School of Medicine
- Dec 2026Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived OrganoidsPhase 2 · Roland Seiler-Blarer
- Mar 2027MicroRNA Profiles in Triple Negative Breast CancerPhase 2 · University College Hospital, Ibadan
- Jun 2027A Study for the Neoadjuvant Treatment of Breast CancerPhase 4 · Second Affiliated Hospital, School of Medicine, Zhejiang University
- Jul 2027A Study for the Adjuvant Treatment of Breast CancerPhase 4 · Second Affiliated Hospital, School of Medicine, Zhejiang University
- Jul 2027Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyPhase 1/2 · Liu Shu
Studies
Open first, then newest update. How each study uses Epirubicin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 155
- Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic CarcinomaRecruitingPhase 2Eye & ENT Hospital of Fudan UniversityNCT07616141Written as EpirubicinHow we know
- Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived OrganoidsNot yet recruitingPhase 2Hospital Centre Biel/BienneNCT06227065Written as EpirubicinHow we know
- Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruitingPhase 1/2Liu ShuNCT07739485Written as Epirubicin and cyclophosphamide followed by paclitaxel oral solutionHow we know
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as EpirubicinHow we know
- Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective StudyRecruitingPhase 2Eye & ENT Hospital of Fudan UniversityNCT07320508Written as Epirubicin (E)How we know
- MicroRNA Profiles in Triple Negative Breast CancerRecruitingPhase 2University College Hospital, IbadanNCT04771871Written as EpirubicinHow we know
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast CancerRecruitingPhase 2University of ChicagoNCT06291064Written as EpirubicinHow we know
- A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerRecruitingPhase 3Fudan UniversityNCT05862064Written as epirubicin,cyclophosphamide,paclitaxel,CarrelizumabHow we know
- A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of BreastRecruitingPhase 1Shanghai Jiao Tong University School of MedicineNCT02897700Written as cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)How we know
- Epirubicin for the Treatment of Sepsis & Septic ShockRecruitingPhase 2Jena University HospitalNCT05033808Written as EpirubicinHow we know
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingPhase 1Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06121570Written as EpirubicinHow we know
- A Study for the Adjuvant Treatment of Breast CancerRecruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05420467Written as EpirubicinHow we know
- A Study for the Neoadjuvant Treatment of Breast CancerRecruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05420454Written as EpirubicinHow we know
- Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer PatientsRecruitingPhase 1/2Peking University People's HospitalNCT04836156Written as neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancerHow we know
- A Study of Genetic Based Chemotherapy Dosing for Breast Cancer PatientsRecruitingPhase 2AHS Cancer Control AlbertaNCT01740271Written as EpirubicinHow we know
- Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived OrganoidsActive, not recruitingPhase 2Roland Seiler-BlarerNCT05024734Written as EpirubicinHow we know
- A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 StudyCompletedPhase 1Hospices Civils de LyonNCT02392845Written as Combination of Docetaxel (DTX) and Epirubicin (EPI)How we know
- VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaCompletedPhase 2Henan Cancer HospitalNCT04433156Written as EpirubicinHow we know
- Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast CancerCompletedPhase 1/2NCIC Clinical Trials GroupNCT00066443Written as epirubicin hydrochlorideHow we know
- PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC TrialActive, not recruitingPhase 2Haukeland University HospitalNCT02624973Written as Adjuvant Epirubicin+ CyclophosphamideHow we know
See all 155 studies that test Epirubicin →
Given beside what is tested · 133 — Epirubicin is usual care or a partner of the new treatment
- A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07900516Written as EpirubicinHow we know
- Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT06860529Written as EpirubicinHow we know
- Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07753642Written as EpirubicinHow we know
- Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast CancerRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06964906Written as Epirubicin (E)How we know
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerRecruitingPhase 3Shanghai JMT-Bio Inc.NCT07441460Written as EpirubicinHow we know
- Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCRecruitingPhase 2Vandana AbramsonNCT07016399Written as EpirubicinHow we know
- Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BCRecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT06500208Written as Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamideHow we know
- Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingPhase 2Wuhan Union Hospital, ChinaNCT06140966Written as epirubicinHow we know
- ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.Not yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT06699576Written as EpirubicinHow we know
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as EpirubicinHow we know
- To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast CancerNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06470633Written as EpirubicinHow we know
- To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast CancerRecruitingPhase 2RemeGen Co., Ltd.NCT06389006Written as EpirubicinHow we know
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT06404463Written as EpirubicinHow we know
- Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast CancerRecruitingPhase 2RemeGen Co., Ltd.NCT06227117Written as Sequential EpirubicinHow we know
- Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant ChemotherapyRecruitingPhase 2wang shusenNCT05978648Written as EpirubicinHow we know
- Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast CancerNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05983094Written as EpirubicinHow we know
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingPhase 1/2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05981014Written as EpirubicinHow we know
- Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk FactorsNot yet recruitingPhase 2Liaoning Cancer Hospital & InstituteNCT05887726Written as EpirubicinHow we know
- Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)RecruitingPhase 2West China HospitalNCT05447702Written as EpirubicinHow we know
- Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05834582Written as Epirubicin+CyclophosphamideHow we know
Showing 20 of 133.
As the comparator · 49 — what is tested is compared with Epirubicin
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06966700Written as EpirubicinHow we know
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Epirubicin hydrochlorideHow we know
- TCb vs EC-T in High Risk ER+/HER2- Breast CancerRecruitingPhase 3Fudan UniversityNCT05901428Written as EpirubicinHow we know
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07424287Written as Epirubicin Hydrochloride for InjectionHow we know
- Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer (EBC)RecruitingPhase 2Hebei Medical University Fourth HospitalNCT06107673Written as Epirubicin Hydrochloride InjectionHow we know
- Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast CancerRecruitingPhase 2Hebei Medical University Fourth HospitalNCT04138719Written as Nab-paclitaxel + EpirubicinHow we know
- Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingPhase 2Karolinska University HospitalNCT05900206Written as EpirubicinHow we know
- Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer PatientsNot yet recruitingPhase 3Fudan UniversityNCT06795503Written as Epirubicin, cyclophosphamide plus paclitaxelHow we know
- EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerRecruitingPhase 3Fudan UniversityNCT05883852Written as EpirubicinHow we know
- The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.Not yet recruitingPhase 2Peng LiuNCT05816694Written as Cisplatin plus Epirubicin plus CyclophosphamideHow we know
- To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical StudyRecruitingNot applicableShanghai Pudong HospitalNCT05656079Written as EpirubicinHow we know
- A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC PatientsRecruitingPhase 3Jiangsu Yahong Meditech Co., Ltd aka AsierisNCT04736394Written as Epirubicin HydrochlorideHow we know
- Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast CancerRecruitingPhase 3Peking UniversityNCT02535221Written as Epirubicin+CTX+5-FuHow we know
- Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast CancerRecruitingPhase 4Shengjing HospitalNCT04136782Written as Epirubicin combined with docetaxelHow we know
- Combination Therapy of Anthracyclines for Children With NephroblastomaNot yet recruitingPhase 4Shengjing HospitalNCT03892330Written as PharmorubicinHow we know
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerActive, not recruitingPhase 3AstraZenecaNCT06112379Written as EpirubicinHow we know
- Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerActive, not recruitingPhase 3Fudan UniversityNCT04193059Written as EpirubicinHow we know
- Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant ChemotherapyCompletedPhase 3Italian Sarcoma GroupNCT01710176Written as epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)How we know
- Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)Active, not recruitingPhase 3Fudan UniversityNCT04296175Written as EpirubicinHow we know
- ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBCActive, not recruitingPhase 2Sun Yat-sen UniversityNCT04172259Written as EpirubicinHow we know
Showing 20 of 49.
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic CarcinomaNov 3, 2026NCT07616141
Codes
What other systems call Epirubicin · ClinicalTrials.gg INT008452
- MeSH (NLM) D015251EpirubicinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3Z8479ZZ5XEPIRUBICINConfirmed FDA, NLM, Wikidata
- RxNorm 3995Confirmed FDA, Wikidata
- Wikidata Q425122epirubicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62028EpirubicinOne source FDA
- DrugBank DB00445One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D015251 | Epirubicin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3Z8479ZZ5X | EPIRUBICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3995 | — | Confirmed FDA, Wikidata |
| Wikidata | Q425122 | epirubicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62028 | Epirubicin | One source FDA |
| DrugBank | DB00445 | — | One source Wikidata |
Also registered as epirubicin hydrochloride (UNII 22966TX7J5 · RxNorm 203213).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.